Article Text

Download PDFPDF
Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine
  1. O. Jarrett, BVMS, PhD, MRCVS, FRSE1 and
  2. J.-P. Ganière, DVM2
  1. 1 University of Glasgow, Department of Veterinary Pathology, Bearsden, Glasgow G61 1QH
  2. 2 Ecole Nationale Vétérinaire de Nantes, Unité de Pathologie Infectieuse, CP3013, 44087 Nantes Cedex 03, France


The efficacy of three feline leukaemia virus (FeLV) vaccines was compared. Kittens were immunised with either a recombinant subunit vaccine, Leucogen, or one of two inactivated virus vaccines, Leukocell 2 or Leucat. On subsequent challenge by intraperitoneal inoculation of FeLV of subgroup A (FeLV-A), only Leucogen gave significant protection. In a second experiment, kittens vaccinated with Leucogen were protected against oronasal challenge with a phenotypic mixture of FeLV of subgroups A, B and C. These results indicate that a recombinant vaccine, containing only the protein moiety of the surface glycoprotein of FeLV-A, can provide better protection than the inactivated virus vaccines tested against challenge with virus of the same subgroup, and can also protect against challenge by all three subgroups of FeLV.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.